TrialClinical immunology (Orlando, Fla.)2014

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

Carla Casulo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.